OSI Pharma's Recent Data Mixed
OSI Pharmaceuticals, Inc. (OSIP - Analyst Report), is a biotechnology company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of oncology, diabetes, and obesity in the U.S.
Tarceva sales continued to grow in both US and rest of the world in 3Q08 but at a declining rate. We believe Tarceva will achieve blockbuster status with over $1 billion in sales in 2008. We remain excited about the revenue from the company's DPP-IV estate. Additionally, the company's pipeline targets diseases like diabetes, obesity and cancer -- the very specific areas where OSI's strengths lie.
We are happy to hear about the positive data from SATURN trial, but disappointed with the negative data from the BETA trial. We maintain our Hold rating for OSIP with a price target of $36.
Read the full analyst report on OSIP
|
|
|
Share |
RSS |
Rate Pos |
Rate Neg |
Comment |
|
|
||||||
Loading Stories...Most Popular on Zacks.com
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | Nov 04, 2009 16:29 pm ET |
Sponsored Links

Sponsored Links 
-2.14 %

30.23
[CLICK TO CLOSE X]